Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei.
Pseudomyxoma peritonei
cytoreductive surgical procedures
fibrinogen
hemostasis
thrombelastography
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
23
08
2019
revised:
18
10
2019
accepted:
22
10
2019
pubmed:
28
10
2019
medline:
15
5
2021
entrez:
27
10
2019
Statut:
ppublish
Résumé
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis. To compare hemostatic efficacy and safety of human fibrinogen concentrate (HFC) vs cryoprecipitate as fibrinogen sources for bleeding patients with acquired fibrinogen deficiency undergoing PMP CRS. FORMA-05 was an off-label single-center, prospective, randomized, controlled phase 2 study. Patients undergoing PMP surgery with predicted intraoperative blood loss ≥2 L received human fibrinogen concentrate (HFC; 4 g) or cryoprecipitate (two pools of 5 units, containing approximately 4.0-4.6 g fibrinogen), repeated as needed. The primary endpoint was a composite of intraoperative and postoperative efficacy, graded using objective 4-point scales and adjudicated by an independent committee. One hundred percent of patients receiving HFC (95% confidence interval: 83.9-100.0, n = 21) or cryoprecipitate (84.6-100.0, n = 22) achieved hemostatic success. HFC demonstrated noninferior efficacy (P = .0095; post hoc) and arrived in the operating room 46 minutes faster. There were significantly greater mean increases with HFC vs cryoprecipitate in plasma fibrinogen (0.78 vs 0.35 g/L; P < .0001) and FIBTEM A20 (3.33 vs 0.93 mm; P = .003). Factor XIII, factor VIII, and von Willebrand factor activity were maintained throughout surgery. Only red blood cells were transfused intraoperatively (median units: HFC group, 1.0; cryoprecipitate group, 0.5). Thromboembolic events were detected with cryoprecipitate only. Safety was otherwise comparable between groups. Human fibrinogen concentrate was hemostatically efficacious in patients undergoing major abdominal PMP surgery, with a favorable safety profile. These results are relevant to other surgical settings where bleeding and acquired fibrinogen deficiency occur.
Sections du résumé
BACKGROUND
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis.
OBJECTIVES
To compare hemostatic efficacy and safety of human fibrinogen concentrate (HFC) vs cryoprecipitate as fibrinogen sources for bleeding patients with acquired fibrinogen deficiency undergoing PMP CRS.
METHODS
FORMA-05 was an off-label single-center, prospective, randomized, controlled phase 2 study. Patients undergoing PMP surgery with predicted intraoperative blood loss ≥2 L received human fibrinogen concentrate (HFC; 4 g) or cryoprecipitate (two pools of 5 units, containing approximately 4.0-4.6 g fibrinogen), repeated as needed. The primary endpoint was a composite of intraoperative and postoperative efficacy, graded using objective 4-point scales and adjudicated by an independent committee.
RESULTS
One hundred percent of patients receiving HFC (95% confidence interval: 83.9-100.0, n = 21) or cryoprecipitate (84.6-100.0, n = 22) achieved hemostatic success. HFC demonstrated noninferior efficacy (P = .0095; post hoc) and arrived in the operating room 46 minutes faster. There were significantly greater mean increases with HFC vs cryoprecipitate in plasma fibrinogen (0.78 vs 0.35 g/L; P < .0001) and FIBTEM A20 (3.33 vs 0.93 mm; P = .003). Factor XIII, factor VIII, and von Willebrand factor activity were maintained throughout surgery. Only red blood cells were transfused intraoperatively (median units: HFC group, 1.0; cryoprecipitate group, 0.5). Thromboembolic events were detected with cryoprecipitate only. Safety was otherwise comparable between groups.
CONCLUSIONS
Human fibrinogen concentrate was hemostatically efficacious in patients undergoing major abdominal PMP surgery, with a favorable safety profile. These results are relevant to other surgical settings where bleeding and acquired fibrinogen deficiency occur.
Identifiants
pubmed: 31654548
doi: 10.1111/jth.14665
pmc: PMC7027898
pii: S1538-7836(22)01502-1
doi:
Substances chimiques
Hemostatics
0
Fibrinogen
9001-32-5
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
352-363Informations de copyright
© 2019 Octapharma. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Références
J Thorac Cardiovasc Surg. 2009 Sep;138(3):694-702
pubmed: 19698858
Surg Oncol Clin N Am. 2003 Jul;12(3):585-603
pubmed: 14567019
Dis Colon Rectum. 1987 Oct;30(10):772-9
pubmed: 2820671
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1647-55
pubmed: 24951020
Can J Surg. 1989 May;32(3):164-70
pubmed: 2713770
Transfus Med. 2016 Apr;26(2):118-22
pubmed: 27030339
Biologicals. 2018 Mar;52:72-77
pubmed: 29336864
Br J Surg. 1998 Oct;85(10):1332-9
pubmed: 9782010
Crit Care. 2019 Mar 27;23(1):98
pubmed: 30917843
J Cardiothorac Vasc Anesth. 2015;29(3):694-702
pubmed: 25836953
Br J Anaesth. 2014 Dec;113(6):922-34
pubmed: 24972790
Eur J Anaesthesiol. 2017 Jun;34(6):332-395
pubmed: 28459785
Int J Surg Oncol. 2011;2011:468698
pubmed: 22312509
J Am Heart Assoc. 2015 Jun 02;4(6):e002066
pubmed: 26037084
Transfus Apher Sci. 2012 Apr;46(2):159-62
pubmed: 22227402
Vox Sang. 2018 Feb;113(2):120-127
pubmed: 29238971
Transfus Med. 2012 Oct;22(5):344-9
pubmed: 22994449
Br J Anaesth. 2010 May;104(5):555-62
pubmed: 20348140
Eur J Surg Oncol. 2008 Feb;34(2):196-201
pubmed: 17524597
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
Gastroenterol Res Pract. 2012;2012:635314
pubmed: 22927838
Anesthesiology. 2013 Jan;118(1):40-50
pubmed: 23249928
Singapore Med J. 2017 Aug;58(8):488-496
pubmed: 27121920
PLoS One. 2018 Jun 21;13(6):e0193657
pubmed: 29927924
Acta Anaesthesiol Scand. 2016 Sep;60(8):1033-42
pubmed: 27109179
Crit Care. 2011;15(2):R83
pubmed: 21375741
Br J Anaesth. 2016 Jul;117(1):41-51
pubmed: 27317703
J Thromb Haemost. 2020 Feb;18(2):352-363
pubmed: 31654548
Br J Haematol. 2010 Jun;149(6):834-43
pubmed: 20456356
Crit Care. 2010;14(2):R55
pubmed: 20374650
Br J Anaesth. 2009 Jun;102(6):785-92
pubmed: 19411671
Cancer. 2008 Jul 15;113(2):315-25
pubmed: 18473354
Transfusion. 2013 Jan;53 Suppl 1:91S-95S
pubmed: 23301979
Crit Care. 2015 Mar 12;19:83
pubmed: 25880548
Br J Anaesth. 2008 Dec;101(6):769-73
pubmed: 18818192
Transfusion. 2014 May;54(5):1379-87
pubmed: 24192484